Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 USD | -0.91% | -0.46% | -36.63% |
06-05 | DarioHealth Appoints Steven Nelson as Chief Commercial Officer | MT |
06-05 | DarioHealth Corp. Announces Management Changes | CI |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 14.67 | 116 | 215 | 109.9 | 46.81 | 32.62 | - | - |
Enterprise Value (EV) 1 | 14.67 | 116 | 215 | 109.9 | 46.81 | 32.62 | 32.62 | 32.62 |
P/E ratio | -0.82 x | -3.56 x | -3.19 x | -1.69 x | -0.89 x | -0.66 x | -0.78 x | -0.8 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 1.94 x | 15.3 x | 10.5 x | 3.97 x | 2.3 x | 0.96 x | 0.71 x | 0.49 x |
EV / Revenue | 1.94 x | 15.3 x | 10.5 x | 3.97 x | 2.3 x | 0.96 x | 0.71 x | 0.49 x |
EV / EBITDA | -0.96 x | -6.23 x | -4.6 x | -3.1 x | -1.49 x | -1.09 x | -3.6 x | 5.28 x |
EV / FCF | - | -6.49 x | -4.08 x | - | - | -1.18 x | -3.61 x | -2.27 x |
FCF Yield | - | -15.4% | -24.5% | - | - | -84.9% | -27.7% | -44% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 2,236 | 8,114 | 16,576 | 25,679 | 27,215 | 29,923 | - | - |
Reference price 2 | 6.560 | 14.29 | 12.97 | 4.280 | 1.720 | 1.090 | 1.090 | 1.090 |
Announcement Date | 17/03/20 | 09/03/21 | 22/03/22 | 09/03/23 | 28/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 7.559 | 7.576 | 20.51 | 27.66 | 20.35 | 33.9 | 46.2 | 66.97 |
EBITDA 1 | -15.26 | -18.61 | -46.69 | -35.5 | -31.5 | -30.05 | -9.05 | 6.182 |
EBIT 1 | -17.7 | -29.9 | -76.49 | -56.81 | -56.19 | -64.18 | -48.37 | - |
Operating Margin | -234.22% | -394.71% | -372.9% | -205.42% | -276.09% | -189.32% | -104.69% | - |
Earnings before Tax (EBT) 1 | -17.74 | -29.44 | -76.73 | -62.19 | -59.36 | -55.49 | -48.37 | - |
Net income 1 | -20.89 | -33.1 | -78.77 | -63.84 | -63.51 | -56.96 | -49.64 | -46.79 |
Net margin | -276.37% | -436.95% | -383.98% | -230.82% | -312.06% | -168.03% | -107.44% | -69.87% |
EPS 2 | -8.000 | -4.010 | -4.070 | -2.540 | -1.930 | -1.640 | -1.405 | -1.360 |
Free Cash Flow 1 | - | -17.85 | -52.68 | - | - | -27.68 | -9.034 | -14.35 |
FCF margin | - | -235.67% | -256.79% | - | - | -81.66% | -19.55% | -21.42% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 17/03/20 | 09/03/21 | 22/03/22 | 09/03/23 | 28/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 6.028 | 8.059 | 6.183 | 6.605 | 6.809 | 7.066 | 6.152 | 3.518 | 3.616 | 5.758 | 7.916 | 9.781 | 10.44 | 12 | 12.86 |
EBITDA 1 | -14.99 | -9.861 | -11.21 | -8.327 | -6.005 | -6.245 | -8.634 | -9.151 | -6.156 | -8.968 | -10.2 | -6.097 | -4.723 | -1.474 | -0.683 |
EBIT 1 | -21.66 | -15.87 | -17.36 | -14.57 | -9.01 | -12.41 | -14.02 | -15.55 | -14.22 | -17.86 | -17.78 | -14.96 | -13.58 | - | - |
Operating Margin | -359.41% | -196.95% | -280.69% | -220.64% | -132.32% | -175.6% | -227.89% | -441.9% | -393.11% | -310.09% | -224.67% | -152.91% | -130.03% | - | - |
Earnings before Tax (EBT) 1 | -21.55 | -15.92 | -18.03 | -15.63 | -12.61 | -12.82 | -16.58 | -15.73 | -14.22 | -9.169 | -17.78 | -14.96 | -13.58 | - | - |
Net income 1 | -22.07 | -16.37 | -18.46 | -16.13 | -12.88 | -12.82 | -18.28 | -15.73 | -15.51 | -7.175 | -19.27 | -15.36 | -14.13 | -13.23 | -12.67 |
Net margin | -366.14% | -203.09% | -298.58% | -244.15% | -189.19% | -181.5% | -297.07% | -447.19% | -428.82% | -124.61% | -243.45% | -157.07% | -135.31% | -110.29% | -98.49% |
EPS 2 | -1.090 | -0.7400 | -0.7400 | -0.6400 | -0.5100 | -0.4500 | -0.5800 | -0.4900 | -0.4100 | -0.2000 | -0.5550 | -0.4450 | -0.4050 | -0.3800 | -0.3700 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 22/03/22 | 12/05/22 | 15/08/22 | 14/11/22 | 09/03/23 | 11/05/23 | 10/08/23 | 02/11/23 | 28/03/24 | 15/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -17.9 | -52.7 | - | - | -27.7 | -9.03 | -14.3 |
ROE (net income / shareholders' equity) | - | - | -91.1% | -57.2% | - | -26.6% | -2.2% | 6.1% |
ROA (Net income/ Total Assets) | - | - | -76.1% | -43.1% | - | -15.4% | -1.3% | 3.8% |
Assets 1 | - | - | 103.6 | 148.2 | - | 369.9 | 3,818 | -1,231 |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | 0.12 | 0.26 | 0.44 | - | 0.67 | 0.74 | 0.81 |
Capex / Sales | - | 1.56% | 1.27% | 1.6% | - | 1.98% | 1.6% | 1.21% |
Announcement Date | 17/03/20 | 09/03/21 | 22/03/22 | 09/03/23 | 28/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.63% | 32.62M | |
-3.18% | 185B | |
-2.68% | 105B | |
-2.23% | 68.9B | |
-6.46% | 46.16B | |
+5.42% | 40.75B | |
+20.09% | 31.11B | |
+11.36% | 24.26B | |
-6.67% | 23.94B | |
-12.70% | 21.86B |
- Stock Market
- Equities
- DRIO Stock
- Financials DarioHealth Corp.